Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 18:9:3180.
doi: 10.3389/fimmu.2018.03180. eCollection 2018.

Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells

Alka Dwivedi  1 , Atharva Karulkar  1 , Sarbari Ghosh  1 , Afrin Rafiq  1 , Rahul Purwar  1
Affiliations
Review

Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells

Alka Dwivedi et al. Front Immunol. .

Erratum in

Abstract

Lymphocytes especially autologous T cells have been used for the treatment of numerous indications including cancers, autoimmune disorders and infectious diseases. Very recently, FDA approved Chimeric Antigen Receptor T cells (CAR T cells) therapy for relapse and refractory CD19+ B cell acute lymphoblastic leukemia (r/r B-ALL) and r/r diffuse large B cell lymphoma (r/r DLBCL) upon their remarkable success in multiple Phase I-II clinical trials. While CAR T cells are considered as major breakthrough in the field of cancer immunotherapy, the regulation of CAR T cells remains poorly understood. In this review we will discuss the strategies that regulate the CAR T cells efficacy and persistence with focus on roles of different structural component of CAR construct. Different domains of CAR construct, for example, antigen binding domain, hinge, transmembrane, and signaling domain as well as immune-regulatory cytokines have significant impact on CAR T cell efficacy. Finally, this review will highlight the strategies that will promote CAR T cells efficacy and will reduce the toxicity.

Keywords: anti-tumor efficacy; cancer immunotherapy; chimeric antigen receptor; cytokines; immunoregulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of different regulatory components of Chimeric Antigen Receptor (CAR) T cells.
See this image and copyright information in PMC

References

    1. Miliotou AN, Papadopoulou LC. CAR T-cell Therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. (2018) 19:5–18. 10.2174/1389201019666180418095526 - DOI - PubMed
    1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. (2013) 368:1509–18. 10.1056/NEJMoa1215134 - DOI - PMC - PubMed
    1. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. (2011) 3:95ra73. 10.1126/scitranslmed.3002842 - DOI - PMC - PubMed
    1. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 123:2625–35. 10.1182/blood-2013-11-492231 - DOI - PMC - PubMed
    1. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. (2018) 11:22. 10.1186/s13045-018-0568-6 - DOI - PMC - PubMed

Publication types

LinkOut - more resources